Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Continuing our track record of consistent top-line growth, margin expansion, strong FCF Consistent strong operating performance driven by IM IM Sales USD bn, % CAGR CC +7% 42.0 39.0 37.7 34.9 IM Core Oplnc USD bn, % CAGR CC +13% 15.2 13.6 12.7 11.2 IM Core Margin (%), growth bps cc Group FCF Cont. Ops, USD bn, % CAGR USD +130bps 36.2 +220bps 35.0 +6% 13.3 11.3 +180bps 33.5 32.0 FY 2018 FY 2019 FY 2020 FY 2021 FY 2018 FY 2019 FY 2020 FY 2021 FY 2018 FY 2019 FY 2020 FY 2021 FY 2018 FY 2021 IM Innovative Medicines 7 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation